MDT · 10-Q · 2026Q3 · Full report

Cardiovascular Product Growth

Medtronic plc · 2026-09-03 · Importance 30 · Surprise 40 · In source text

Interventional Cardiology Therapies sales increased 7%, led by TAVR, the Symplicity Spyral renal denervation system, guide catheters, and balloons. CardioVascular Surgery sales increased 9%, supported by Aortic products, the Avalus Ultra surgical valve, and the VitalFlow ECMO system. Peripheral Vascular Health sales increased 12%, driven by Peripheral Vascular and endoVenous growth. The company expects continued adoption of Evolut TAVR, Onyx Frontier drug-eluting stents, Prevail drug-coated balloons, VitalFlow ECMO, Penditure, IN.PACT 018, Neuroguard IEP, and Liberant.

Key facts

• The U.S. Centers for Medicare and Medicaid Services finalized National Coverage Determination for the Symplicity Spyral renal denervation system in October 2025. source
• Penditure LAA Exclusion System received CE Mark in October 2025. source
• Cardiovascular net sales for the three months ended July 31, 2026 were $3,927 million compared to $3,285 million for the three months ended July 25, 2025, an increase of 20 percent. source
• VitalFlow Transport Frame Air and Ground, an accessory to VitalFlow ECMO system, received CE Mark in May 2026. source
• Peripheral Vascular Health net sales for the three months ended July 31, 2026 increased 12 percent compared to the corresponding period in the prior fiscal year. source
• Interventional Cardiology Therapies net sales for the three months ended July 31, 2026 increased 7 percent compared to the corresponding period in the prior fiscal year. source
• CardioVascular Surgery net sales for the three months ended July 31, 2026 increased 9 percent compared to the corresponding period in the prior fiscal year. source

Impact estimates